Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 9, 2018
Translation in Brief

The fate of NK cells

Differentiation states of CAR-transfected NK cells influence anticancer function
BioCentury | Apr 7, 2017
Finance

Combo quest

Why NantKwest led Viracta’s B round
BioCentury | Feb 10, 2017
Clinical News

Lirilumab: Ph II EffiKIR data

BioCentury | Feb 6, 2017
Clinical News

Innate's lirilumab fails Phase II AML trial

BioCentury | Jan 12, 2017
Company News

Innate Pharma, Bristol-Myers deal

BioCentury | Nov 11, 2016
Clinical News

Lirilumab: Ph I/II CA223-001 data

BioCentury | Nov 9, 2016
Clinical News

Lirilumab combo shows early promise in SCCHN

BioCentury | Nov 5, 2016
Finance

Vive la biotech

Why investors are paying more attention to French biotech
Items per page:
1 - 10 of 35